Sarepta Therapeutics (SRPT) had its price target raised by Citigroup Inc. from $9.00 to $13.00. They now have a "sell" rating on the stock.
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Sarepta Therapeutics (SRPT) had its "underperform" rating reaffirmed by Needham & Company LLC.
Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results Spark Share Price Rebound [Yahoo! Finance]
Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results [Yahoo! Finance]